Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 12/20 | 0.44 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16990656 | 0.90 | HTT (0.59) | DDR2HTTP2RX3 | |
| SCHEMBL15575325 | 0.89 | DDR2 (0.59) | DDR2CA9P2RX3RAF1 | |
| SCHEMBL16990647 | 0.87 | RAB9A (0.52) | DDR2HTTCA9P2RX3RAF1 | |
| SCHEMBL16990609 | 0.86 | DDR2 (0.45) | DDR2HTTP2RX3 | |
| SCHEMBL15575399 | 0.86 | HTT (0.60) | HTTCA12CA1CA2CA9 | |
| SCHEMBL16990605 | 0.85 | DDR2 (0.49) | DDR2P2RX3 | |
| SCHEMBL16990632 | 0.85 | DDR2 (0.57) | DDR2HTTP2RX3RAF1 | |
| SCHEMBL15573350 | 0.84 | P2RX3 (0.44) | DDR2P2RX3RAF1 | |
| SCHEMBL15574618 | 0.84 | DDR2 (0.55) | DDR2RAF1 | |
| SCHEMBL16990602 | 0.84 | MEN1 (0.50) | DDR2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | DDR2 1/4885HTT 3579/4885CA12 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.